Hypoxia, hypoxia-inducible transcription factors, and renal cancer

European Urology

Volumn 69, Issue 4, 2016, Pages 646-657

  Schödel, Johannes ^a   Grampp, Steffen ^a   Maher, Eamonn R ^b,c   Moch, Holger ^d   Ratcliffe, Peter J ^e   Russo, Paul ^f,g   Mole, David R ^e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clear cell renal cell carcinoma; Hypoxia; Hypoxia inducible transcription factors; von Hippel Lindau

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; PROTEASOME; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

CHROMOSOME DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HYPOXIA; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; UBIQUITINATION; ANIMAL; BIOSYNTHESIS; CARCINOMA, RENAL CELL; CELL HYPOXIA; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; OXYGEN; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84959507012     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.08.007     Document Type: Review

References (135)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. J. Ferlay, I. Soerjomataram, R. Dikshit, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
3. B. Ljungberg, S.C. Campbell, H.Y. Choi, and et al. The epidemiology of renal cell carcinoma Eur Urol 60 2011 615 621
4. B. Shuch, A. Amin, A.J. Armstrong, and et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity Eur Urol 67 2015 85 97
5. J. Verine, A. Pluvinage, G. Bousquet, and et al. Hereditary renal cancer syndromes: an update of a systematic review Eur Urol 58 2010 701 710
6. J.R. Gnarra, K. Tory, Y. Weng, and et al. Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
7. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 2013 43 49
8. J.G. Herman, F. Latif, Y. Weng, and et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proc Natl Acad Sci U S A 91 1994 9700 9704
9. O. Iliopoulos, A. Kibel, S. Gray, and W.G. Kaelin Jr. Tumour suppression by the human von Hippel-Lindau gene product Nat Med 1 1995 822 826
10. A. Kibel, O. Iliopoulos, J.A. DeCaprio, and W.G. Kaelin Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C Science 269 1995 1444 1446
11. Y. Sato, T. Yoshizato, Y. Shiraishi, and et al. Integrated molecular analysis of clear-cell renal cell carcinoma Nat Genet 45 2013 860 867
12. 2 sensing Science 292 2001 464 468
13. 2-regulated prolyl hydroxylation Science 292 2001 468 472
14. M.E. Cockman, N. Masson, D.R. Mole, and et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 2000 25733 25741
15. P.H. Maxwell, M.S. Wiesener, G.W. Chang, and et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275
16. R.H. Wenger, D.P. Stiehl, and G. Camenisch Integration of oxygen signaling at the consensus HRE Sci STKE 2005 2005 re12
17. J. Schodel, S. Oikonomopoulos, J. Ragoussis, C.W. Pugh, P.J. Ratcliffe, and D.R. Mole High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq Blood 117 2011 e207 e217
18. J.S. Isaacs, Y.J. Jung, D.R. Mole, and et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability Cancer Cell 8 2005 143 153
19. C.M. Kim, C. Vocke, C. Torres-Cabala, and et al. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors J Urol 175 2006 1908 1914
20. M.A. Selak, S.M. Armour, E.D. MacKenzie, and et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 2005 77 85
21. P.J. Pollard, B. Spencer-Dene, D. Shukla, and et al. Targeted inactivation of FH1 causes proliferative renal cyst development and activation of the hypoxia pathway Cancer Cell 11 2007 311 319
22. 2 availability on human cancer Nat Rev Cancer 8 2008 967 975
23. F. Latif, K. Tory, J. Gnarra, and et al. Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320
24. L. Li, L. Zhang, X. Zhang, and et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations Mol Cell Biol 27 2007 5381 5392
25. S.C. Clifford, M.E. Cockman, A.C. Smallwood, and et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease Hum Mol Genet 10 2001 1029 1038
26. M.A. Hoffman, M. Ohh, H. Yang, J.M. Klco, M. Ivan, and W.G. Kaelin Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 10 2001 1019 1027
27. A. Takahashi, H. Sasaki, S.J. Kim, and et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis Cancer Res 54 1994 4233 4237
28. Y. Nagase, K. Takata, N. Moriyama, Y. Aso, T. Murakami, and H. Hirano Immunohistochemical localization of glucose transporters in human renal cell carcinoma J Urol 153 1995 798 801
29. Y. Liu, S.R. Cox, T. Morita, and S. Kourembanas Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer Circ Res 77 1995 638 643
30. J.A. Forsythe, B.H. Jiang, N.V. Iyer, and et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol Cell Biol 16 1996 4604 4613
31. 2 in muscle cells in culture Am J Physiol 262 1992 C682 C690
32. O. Iliopoulos, A.P. Levy, C. Jiang, W.G. Kaelin Jr., and M.A. Goldberg Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc Natl Acad Sci U S A 93 1996 10595 10599
33. D.R. Duan, A. Pause, W.H. Burgess, and et al. Inhibition of transcription elongation by the VHL tumor suppressor protein Science 269 1995 1402 1406
34. T. Kishida, T.M. Stackhouse, F. Chen, M.I. Lerman, and B. Zbar Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations Cancer Res 55 1995 4544 4548
35. H. Okuda, S. Hirai, Y. Takaki, and et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes Biochem Biophys Res Commun 263 1999 491 497
36. A.V. Kuznetsova, J. Meller, P.O. Schnell, and et al. von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination Proc Natl Acad Sci U S A 100 2003 2706 2711
37. M. Ohh, R.L. Yauch, K.M. Lonergan, and et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1 1998 959 968
38. A. Grosfeld, I.P. Stolze, M.E. Cockman, and et al. Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor J Biol Chem 282 2007 13264 13269
39. B. Schermer, C. Ghenoiu, M. Bartram, and et al. The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth J Cell Biol 175 2006 547 554
40. G.L. Wang, and G.L. Semenza Purification and characterization of hypoxia-inducible factor 1 J Biol Chem 270 1995 1230 1237
41. G.L. Semenza, and G.L. Wang A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol 12 1992 5447 5454
42. G.L. Wang, and G.L. Semenza Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia J Biol Chem 268 1993 21513 21518
43. H. Tian, S.L. McKnight, and D.W. Russell Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells Genes Dev 11 1997 72 82
44. Y.Z. Gu, S.M. Moran, J.B. Hogenesch, L. Wartman, and C.A. Bradfield Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha Gene Expr 7 1998 205 213
45. A.C. Epstein, J.M. Gleadle, L.A. McNeill, and et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54
46. D. Lando, D.J. Peet, D.A. Whelan, J.J. Gorman, and M.L. Whitelaw Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch Science 295 2002 858 861
47. D. Lando, D.J. Peet, J.J. Gorman, D.A. Whelan, M.L. Whitelaw, and R.K. Bruick FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev 16 2002 1466 1471
48. P. Koivunen, M. Hirsila, V. Gunzler, K.I. Kivirikko, and J. Myllyharju Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases J Biol Chem 279 2004 9899 9904
49. C.P. Bracken, A.O. Fedele, S. Linke, and et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment J Biol Chem 281 2006 22575 22585
50. M.S. Wiesener, J.S. Jurgensen, C. Rosenberger, and et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs FASEB J 17 2003 271 273
51. C. Rosenberger, S. Mandriota, J.S. Jurgensen, and et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys J Am Soc Nephrol 13 2002 1721 1732
52. R.E. Schietke, T. Hackenbeck, M. Tran, and et al. Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts PLoS One 7 2012 e31034
53. X. Xia, M.E. Lemieux, W. Li, and et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis Proc Natl Acad Sci U S A 106 2009 4260 4265
54. D.R. Mole, C. Blancher, R.R. Copley, and et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts J Biol Chem 284 2009 16767 16775
55. A.J. Krieg, E.B. Rankin, D. Chan, O. Razorenova, S. Fernandez, and A.J. Giaccia Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth Mol Cell Biol 30 2010 344 353
56. K. Tanimoto, K. Tsuchihara, A. Kanai, and et al. Genome-wide identification and annotation of HIF-1alpha binding sites in two cell lines using massively parallel sequencing Hugo J 4 2010 35 48
57. I. Mimura, M. Nangaku, Y. Kanki, and et al. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A Mol Cell Biol 32 2012 3018 3032
58. A. Ortiz-Barahona, D. Villar, N. Pescador, J. Amigo, and L. del Peso Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction Nucleic Acids Res 38 2010 2332 2345
59. C.C. Wykoff, C.W. Pugh, P.H. Maxwell, A.L. Harris, and P.J. Ratcliffe Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling Oncogene 19 2000 6297 6305
60. C.C. Wykoff, C. Sotiriou, M.E. Cockman, and et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene Br J Cancer 90 2004 1235 1243
61. Y. Jiang, W. Zhang, K. Kondo, and et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways Mol Cancer Res 1 2003 453 462
62. J. Schodel, D.R. Mole, and P.J. Ratcliffe Pan-genomic binding of hypoxia-inducible transcription factors Biol Chem 394 2013 507 517
63. J. Schodel, C. Bardella, L.K. Sciesielski, and et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression Nat Genet 44 2012 420 425 S1-2
64. G.P. Elvidge, L. Glenny, R.J. Appelhoff, P.J. Ratcliffe, J. Ragoussis, and J.M. Gleadle Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways J Biol Chem 281 2006 15215 15226
65. C. Warnecke, Z. Zaborowska, J. Kurreck, and et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells FASEB J 18 2004 1462 1464
66. C. Warnecke, A. Weidemann, M. Volke, and et al. The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors Exp Cell Res 314 2008 2016 2027
67. S.J. Mandriota, K.J. Turner, D.R. Davies, and et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron Cancer Cell 1 2002 459 468
68. R.R. Raval, K.W. Lau, M.G. Tran, and et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol Cell Biol 25 2005 5675 5686
69. T. Hackenbeck, K.X. Knaup, R. Schietke, and et al. HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia Cell Cycle 8 2009 1386 1395
70. G. Lachance, J. Uniacke, T.E. Audas, and et al. DNMT3a epigenetic program regulates the HIF-2alpha oxygen-sensing pathway and the cellular response to hypoxia Proc Natl Acad Sci U S A 111 2014 7783 7788
71. A.P. Young, and W.G. Kaelin Jr. Senescence triggered by the loss of the VHL tumor suppressor Cell Cycle 7 2008 1709 1712
72. M.M. Walther, I.A. Lubensky, D. Venzon, B. Zbar, and W.M. Linehan Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications J Urol 154 1995 2010 2014 discussion 2014-5
73. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 2002 237 246
74. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 2003 E83
75. C. Shen, R. Beroukhim, S.E. Schumacher, and et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene Cancer Discov 1 2011 222 235
76. J. Adam, E. Hatipoglu, L. O'Flaherty, and et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling Cancer Cell 20 2011 524 537
77. B. Keith, R.S. Johnson, and M.C. Simon HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression Nat Rev Cancer 12 2012 9 22
78. J.D. Gordan, P. Lal, V.R. Dondeti, and et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell 14 2008 435 446
79. F.A. Monzon, K. Alvarez, L. Peterson, and et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis Mod Pathol 24 2011 1470 1479
80. M.P. Purdue, M. Johansson, D. Zelenika, and et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 Nat Genet 43 2011 60 65
81. S.S. Han, M. Yeager, L.E. Moore, and et al. The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma Hum Mol Genet 21 2012 1190 1200
82. F. Audenet, G. Cancel-Tassin, B. Pierre, and et al. Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma J Urol 191 2014 487 492
83. T. Su, Y.F. Han, Y.W. Yu, and et al. A GWAS-identified susceptibility locus on chromosome 11q13.3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma Oncol Lett 6 2013 421 426
84. X. Wu, G. Scelo, M.P. Purdue, and et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23 Hum Mol Genet 21 2012 456 462
85. G.L. Dalgliesh, K. Furge, C. Greenman, and et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 2010 360 363
86. G. van Haaften, G.L. Dalgliesh, H. Davies, and et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat Genet 41 2009 521 523
87. S. Pena-Llopis, S. Vega-Rubin-de-Celis, A. Liao, and et al. BAP1 loss defines a new class of renal cell carcinoma Nat Genet 44 2012 751 759
88. I. Varela, P. Tarpey, K. Raine, and et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma Nature 469 2011 539 542
89. M. Gerlinger, S. Horswell, J. Larkin, and et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing Nat Genet 46 2014 225 233
90. M. Gerlinger, A.J. Rowan, S. Horswell, and et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
91. R.H. Wenger, I. Kvietikova, A. Rolfs, G. Camenisch, and M. Gassmann Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site Eur J Biochem 253 1998 771 777
92. X. Niu, T. Zhang, L. Liao, and et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C Oncogene 31 2012 776 786
93. J.M. Simon, K.E. Hacker, D. Singh, and et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects Genome Res 24 2014 241 250
94. S.S. Wang, Y.F. Gu, N. Wolff, and et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis Proc Natl Acad Sci U S A 111 2014 16538 16543
95. M.N. Khan, T. Bhattacharyya, P. Andrikopoulos, and et al. Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1alpha-mediated apoptosis Br J Cancer 104 2011 1151 1159
96. S.G. Kroeze, J.S. Vermaat, A. van Brussel, and et al. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients Eur J Cancer 46 2010 3375 3382
97. Y. Makino, R. Cao, K. Svensson, and et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression Nature 414 2001 550 554
98. M.A. Maynard, A.J. Evans, T. Hosomi, S. Hara, M.A. Jewett, and M. Ohh Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma FASEB J 19 2005 1396 1406
99. T. Tanaka, M. Wiesener, W. Bernhardt, K.U. Eckardt, and C. Warnecke The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction Biochem J 424 2009 143 151
100. M.A. Maynard, A.J. Evans, W. Shi, W.Y. Kim, F.F. Liu, and M. Ohh Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression Cell Cycle 6 2007 2810 2816
101. P. Zhang, Q. Yao, L. Lu, Y. Li, P.J. Chen, and C. Duan Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia Cell Rep 6 2014 1110 1121
102. T. Klatte, N. Kroeger, E.N. Rampersaud, and et al. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma Cancer 118 2012 5777 5782
103. J.D. Gordan, J.A. Bertout, C.J. Hu, J.A. Diehl, and M.C. Simon HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity Cancer Cell 11 2007 335 347
104. J.D. Gordan, C.B. Thompson, and M.C. Simon HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation Cancer Cell 12 2007 108 113
105. J.A. Bertout, A.J. Majmundar, J.D. Gordan, and et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses Proc Natl Acad Sci U S A 106 2009 14391 14396
106. A.E. Burrows, A. Smogorzewska, and S.J. Elledge Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence Proc Natl Acad Sci U S A 107 2010 14280 14285
107. S. Biswas, P.J. Charlesworth, G.D. Turner, and et al. CD31 angiogenesis and combined expression of HIF-1alpha and HIF-2alpha are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFalpha transcriptional products are not: implications for antiangiogenic trials and HIFalpha biomarker studies in primary CC-RCC Carcinogenesis 33 2012 1717 1725
108. T. Klatte, D.B. Seligson, S.B. Riggs, and et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma Clin Cancer Res 13 2007 7388 7393
109. A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko, and B. Ljungberg The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma Clin Cancer Res 11 2005 1129 1135
110. C.C. Hudson, M. Liu, G.G. Chiang, and et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
111. C.N. Sternberg, I.D. Davis, J. Mardiak, and et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
112. T.K. Choueiri, A.P. Fay, R. Gagnon, and et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma Clin Cancer Res 19 2013 5218 5226
113. T.K. Choueiri, S.A. Vaziri, E. Jaeger, and et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 2008 860 865 discussion 865-6
114. K. Kondo, M. Yao, M. Yoshida, and et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters Genes Chromosomes Cancer 34 2002 58 68
115. D.J. Atkins, C. Gingert, C. Justenhoven, and et al. Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas Virchows Arch 447 2005 634 642
116. M. Yao, M. Yoshida, T. Kishida, and et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma J Natl Cancer Inst 94 2002 1569 1575
117. P. Schraml, K. Struckmann, F. Hatz, and et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma J Pathol 196 2002 186 193
118. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley, and W. Krek Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 425 2003 307 311
119. S. Vanharanta, W. Shu, F. Brenet, and et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer Nat Med 19 2013 50 56
120. P.J. Pollard, C. Loenarz, D.R. Mole, and et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha Biochem J 416 2008 387 394
121. S. Beyer, M.M. Kristensen, K.S. Jensen, J.V. Johansen, and P. Staller The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF J Biol Chem 283 2008 36542 36552
122. D.A. Chan, P.D. Sutphin, P. Nguyen, and et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality Sci Transl Med 3 2011 94ra70
123. E.B. Rankin, K.C. Fuh, L. Castellini, and et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET Proc Natl Acad Sci U S A 111 2014 13373 13378
124. W.H. Tong, C. Sourbier, G. Kovtunovych, and et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels Cancer Cell 20 2011 315 327
125. R.S. Preston, A. Philp, T. Claessens, and et al. Absence of the Birt-Hogg-Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility Oncogene 30 2011 1159 1173
126. C.J. Hu, L.Y. Wang, L.A. Chodosh, B. Keith, and M.C. Simon Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation Mol Cell Biol 23 2003 9361 9374
127. R.I. McCormick, C. Blick, J. Ragoussis, and et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis Br J Cancer 108 2013 1133 1142
128. O.V. Razorenova, E.C. Finger, R. Colavitti, and et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration Proc Natl Acad Sci U S A 108 2011 1931 1936
129. B. Li, B. Qiu, D.S. Lee, and et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression Nature 513 2014 251 255
130. K.X. Knaup, J. Monti, T. Hackenbeck, and et al. Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro Mol Carcinog 53 2014 970 978
131. K. Shoji, T. Murayama, I. Mimura, and et al. Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma Am J Pathol 182 2013 2191 2203
132. K. Grabmaier, M.C. AdW, G.W. Verhaegh, J.A. Schalken, and E. Oosterwijk Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma Oncogene 23 2004 5624 5631
133. T. Gimm, M. Wiese, B. Teschemacher, and et al. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1 FASEB J 24 2010 4443 4458
134. B.L. Petrella, J. Lohi, and C.E. Brinckerhoff Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma Oncogene 24 2005 1043 1052
135. M.F. Salama, B. Carroll, M. Adada, M. Pulkoski-Gross, Y.A. Hannun, and L.M. Obeid A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma FASEB J 29 2015 2803 2813